CME in Minutes: Education in Oncology & Hematology

Answers In CME
  • 5.0 (6)
  • 生命科学
  • 一周一更

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

  1. 5小时前

    Justin F. Gainor, MD - A Blueprint for Action: Integrating Pre- and/or Post-Operative Immunotherapy Into Early-Stage NSCLC Management

    Please visit answersincme.com/99485655-replay860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) use a case-based approach to explore evidence-based strategies to optimize early-stage, resectable NSCLC care with (neo)adjuvant/perioperative immunotherapy, highlighting the role of multidisciplinary teams. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the (neo)adjuvant/perioperative treatment of patients with early-stage, resectable NSCLC; Formulate strategies to appropriately integrate immunotherapy-based (neo)adjuvant/perioperative regimens into treatment plans for patients with early-stage, resectable NSCLC; Discuss multidisciplinary team approaches to enhance care for patients with early-stage, resectable NSCLC.

    53 分钟

  2. 5小时前

    Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

    Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.

    18 分钟

  3. 5小时前

    Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

    Please visit answersincme.com/UDT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses primary chemoimmunotherapy regimens in advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Apply biomarker testing results to guide initial treatment decisions in advanced endometrial cancer; Select the optimal therapy for a given patient with endometrial cancer, based on the latest evidence; Design patient-centered, multidisciplinary care plans that support treatment continuity and patient survivorship.

    20 分钟

  4. 6天前

    Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach

    Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.

    1 小时 4 分钟

  5. 9月22日

    Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

    Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.

    16 分钟

  6. 9月12日

    David Rees, MA, MBBS, FRCPath, FRCPCH, FRCP - Sickle Cell Disease in Perspective: An Expert Point of View on Therapeutic Selection and Comprehensive Care

    Please visit answersincme.com/GTM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in sickle cell disease discusses comprehensive therapeutic selection strategies, from disease-modifying therapies to gene therapy options, and evidence-based approaches for optimizing patient outcomes across the disease spectrum. Upon completion of this activity, participants should be better able to: Review the impact that disease manifestations such as vaso-occlusive crises have on patients with sickle cell disease; Assess the efficacy and safety of available therapies for sickle cell disease and their implications for clinical practice; and Apply evidence-based strategies to optimize treatment outcomes in patients with severe sickle cell disease.

    15 分钟

  7. 9月12日

    Mona Shafey, MD, FRCPC / Nicole Lamanna, MD - Charting the Course: Navigating the Maze of Treatment Selection and Sequencing in CLL

    Please visit answersincme.com/860/240201294-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss how to select and sequence treatments for patients with CLL. Upon completion of this activity, participants should be better able to: Review guideline recommendations for preferred treatments in patients with CLL; Identify the clinical implications of the latest evidence informing the use of second-generation BTK inhibitors in patients with CLL; Outline practical strategies to optimize outcomes with second-generation BTK inhibitors in patients with CLL; and Describe emerging therapeutic agents currently under investigation for the treatment of CLL.

    1 小时 7 分钟

  8. 9月10日

    Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

    Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.

    55 分钟
查看全部 151 集

评分及评论

5
共 5 分
6 个评分

关于

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

信息

更多来自“Answers In CME ”的内容

你可能还喜欢